Editas CEO sells 5,124 shares in tax-plan trade

Editas Medicine’s CEO reported a small, non-discretionary sale of shares under an automatic plan to cover tax withholding from recently vested restricted stock units.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) director and CEO O'Neill Gilmore Neil reported selling 5,124 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share in open-market trades. The sale was made under a Rule 10b5-1 durable automatic sales instruction plan adopted on April 13, 2022 to satisfy tax withholding obligations from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following the sale, the reporting person directly holds 243,189 shares of Editas Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 5,124 shares

Net Sell 1 txn

Insider O'Neill Gilmore Neil

Role CEO

Sold 5,124 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	5,124	$3.0372	$16K

Holdings After Transaction: Common Stock — 243,189 shares (Direct)

Footnotes (2)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 5,124 shares Weighted average sale price: $3.0372 per share Sale price range: $3.0050–$3.0372 per share +3 more

6 metrics

Shares sold 5,124 shares Common stock sold by CEO on September 3, 2026

Weighted average sale price $3.0372 per share Average price for the 5,124 shares sold on September 3, 2026

Sale price range $3.0050–$3.0372 per share Range of prices for multiple trades in the reported transaction

Shares owned after transaction 243,189 shares CEO’s direct holdings of Editas Medicine common stock after the sale

Plan adoption date April 13, 2022 Date the durable automatic sales instruction (Rule 10b5-1) plan was adopted

RSU vesting date September 2, 2026 Vesting of restricted stock units that triggered tax withholding obligation

Key Terms

durable automatic sales instruction plan, restricted stock units, tax withholding obligations, weighted average purchase price

4 terms

durable automatic sales instruction plan financial

"Sale was effected pursuant to a durable automatic sales instruction plan"

restricted stock units financial

"as a result of vesting in restricted stock units on September 2, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sale of shares by the Issuer necessary to meet tax withholding obligations"

weighted average purchase price financial

"The price reported above reflects the weighted average purchase price"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

FAQ

What did Editas Medicine (EDIT) disclose in this Form 4 filing?

The filing reports that CEO and director O'Neill Gilmore Neil sold 5,124 shares of Editas Medicine common stock on September 3, 2026 under an automatic sales plan, primarily to meet tax withholding obligations from vested restricted stock units.

How many EDIT shares did the CEO sell and at what price?

The CEO sold 5,124 shares of Editas Medicine common stock at a weighted average price of $3.0372 per share. The transaction was executed in multiple trades with prices ranging from $3.0050 to $3.0372.

How many Editas Medicine (EDIT) shares does the CEO hold after this transaction?

After the reported sale, CEO O'Neill Gilmore Neil directly holds 243,189 shares of Editas Medicine common stock. This figure is disclosed as the total number of shares directly owned following the September 3, 2026 transaction.

Was the EDIT CEO’s share sale discretionary or part of a trading plan?

The sale is described as non-discretionary and was effected under a durable automatic sales instruction plan treated as a Rule 10b5-1 trading plan, adopted on April 13, 2022, to cover tax withholding from restricted stock unit vesting.

Why did the Editas Medicine (EDIT) CEO sell these shares?

The shares were sold to meet tax withholding obligations arising from the vesting of restricted stock units on September 2, 2026. The footnote states the sale does not represent a discretionary trade by the reporting person.

What price range applied to the CEO’s Editas Medicine (EDIT) share sale?

The transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372 per share. The reported $3.0372 figure is the weighted average price across those trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:23 PM Accepted by SEC EDGAR 09/04/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Gilmore Neil

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		5,124	D	$3.0372(2)	243,189	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Gilmore O'Neill	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)